Kinsella on Liberty Podcast: Episode 465.

On stupid and confused "thickism" see various posts under tag thickism, and Cory Massimino, "Libertarianism is More than Anti-Statism," C4SS (April 8th, 2014).

GROK SHOWNOTES: [0:00–9:16] In this engaging episode of the Kinsella on Liberty podcast, Stephan Kinsella and Sheldon Richman tackle the contentious issue of pharmaceutical price controls under Trump’s executive order, questioning their equivalence to traditional price controls that distort markets. Kinsella, drawing on his extensive critique of intellectual property (Patents and Pharmaceuticals, 2023; Patents, Pharma, Government: The Unholy Alliance, 2024), argues that patents create artificial monopolies, so price controls countering these are not standard interventions but responses to government-granted privileges. Richman highlights FDA-imposed costs, which patents partially offset, though Kinsella counters that these costs are overstated, citing lower drug prices abroad (Drug Reimportation, 2009). They endorse reimportation as a market-based solution, referencing Connor O’Keefe’s analysis (Mises: How Trump Can Lower Drug Prices Without Price Controls, 2025), but criticize Trump’s coercive tactics as resembling a protection racket (Trump’s Worst Idea: Pharmaceuticals, 2025) (0:02–6:00). The discussion also critiques antitrust laws and secondary regulations, with Richman warning against Kevin Carson’s approach of layering controls atop privileges (Kevin Carson on Confiscating Property from the Rich, 2016) (6:00–9:16).

[9:16–1:13:35] The conversation shifts to a robust defense of the corporate form, addressing left-libertarian criticisms of limited liability and shareholder responsibility. Kinsella, aligning with Robert Hessen’s contractual view and his own writings (Corporate Personhood, Limited Liability, and Double Taxation, 2011; Left-Libertarians, Corporations, Expropriating Stakeholders, 2008), argues that limited liability is not a privilege but a logical outcome of action-based responsibility, where shareholders are not liable unless causally responsible for torts (Van Dun on Freedom versus Property and Hostile Encirclement, 2009). Richman decries the pejorative use of “corporate” by figures like Roderick Long, rejecting claims that corporations inherently rely on state favoritism (Comment on Left-Libertarianism on Roderick Long’s Sub-Ex Dep Post, 2009) (9:16–36:01). They explore thick libertarianism, agreeing that individualism connects to broader values but remains distinct, and critique Walter Block’s evictionism on abortion, with Kinsella arguing fetuses are not trespassers due to maternal actions (Together Strong Debate with Walter Block, 2022) (36:01–1:13:35). A lighthearted discussion on pipe tobacco reflects their commitment to personal liberty, underscoring their broader libertarian principles (Wombatrons: Why I Am a Left-Libertarian, 2009).

https://youtu.be/5YaTsoDH9Eg

Grok detailed shownotes:

Detailed Segment Summary for Show Notes

Segment 1: Price Controls, Patents, and Reimportation (0:02–9:16)

Description and Summary: Kinsella andMemphis-based Robert Hessen and Sheldon Richman discuss Trump’s pharmaceutical price control executive order, questioning its implications. Kinsella, per his writings (Patents and Pharmaceuticals, 2023; Patents, Pharma, Government: The Unholy Alliance, 2024), argues that patents create monopoly prices, so price controls countering these aren’t standard market distortions, as patents themselves are government-granted (IP vs. Antitrust, 2005). Richman notes FDA costs inflate drug prices, but Kinsella cites lower prices abroad to argue these costs are overstated (Drug Reimportation, 2009) (0:02–2:28). They advocate reimportation, citing Connor O’Keefe’s market-based approach (Mises: How Trump Can Lower Drug Prices Without Price Controls, 2025), and criticize Trump’s coercive tactics as a protection racket (Trump’s Worst Idea: Pharmaceuticals,